Goldsmith Leighton E, Wiebke Kristy, Seal John, Brinster Clayton, Smith Taylor A, Bazan Hernan A, Sternbergh W Charles
Section of Vascular and Endovascular Surgery, Department of Surgery, Ochsner Clinic, New Orleans, La.
Section of Transplant Surgery, Department of Surgery, Ochsner Clinic, New Orleans, La.
J Vasc Surg. 2017 Nov;66(5):1488-1496. doi: 10.1016/j.jvs.2017.04.062. Epub 2017 Jul 8.
Hepatic artery stenosis (HAS) after liver transplantation can progress to hepatic artery thrombosis (HAT) and a subsequent 30% to 50% risk of graft loss. Although endovascular treatment of severe HAS after liver transplantation has emerged as the dominant method of treatment, the potential risks of these interventions are poorly described.
A retrospective review of all endovascular interventions for HAS after liver transplantation between August 2009 and March 2016 was performed at a single institution, which has the largest volume of liver transplants in the United States. Severe HAS was identified by routine surveillance duplex ultrasound imaging (peak systolic velocity >400 cm/s, resistive index <0.5, and presence of tardus parvus waveforms).
In 1129 liver transplant recipients during the study period, 106 angiograms were performed in 79 patients (6.9%) for severe de novo or recurrent HAS. Interventions were performed in 99 of 106 cases (93.4%) with percutaneous transluminal angioplasty alone (34 of 99) or with stent placement (65 of 99). Immediate technical success was 91%. Major complications occurred in eight of 106 cases (7.5%), consisting of target vessel dissection (5 of 8) and rupture (3 of 8). Successful endovascular treatment was possible in six of the eight patients (75%). Ruptures were treated with the use of a covered coronary balloon-expandable stent graft or balloon tamponade. Dissections were treated with placement of bare-metal or drug-eluting stents. No open surgical intervention was required to manage any of these complications. With a median of follow-up of 22 months, four of eight patients (50%) with a major complication progressed to HAT compared with one of 71 patients (1.4%) undergoing a hepatic intervention without a major complication (P < .001). One patient required retransplantation. Severe vessel tortuosity was present in 75% (6 of 8) of interventions with a major complication compared with 34.6% (34 of 98) in those without (P = .05). In the complication cohort, 37.5% (3 of 8) of the patients had received a second liver transplant before intervention compared with 12.6% (9 of 71) of the patients in the noncomplication cohort (P = .097).
Although endovascular treatment of HAS is safe and effective in most patients, target vessel injury is possible. Severe tortuosity of the hepatic artery and prior retransplantation were associated with a twofold to threefold increased risk of a major complication. Acute vessel injury can be managed successfully using endovascular techniques, but these patients have a significant risk of subsequent HAT and need close surveillance.
肝移植术后肝动脉狭窄(HAS)可进展为肝动脉血栓形成(HAT),进而导致移植物丢失风险达30%至50%。尽管肝移植术后严重HAS的血管内治疗已成为主要治疗方法,但这些干预措施的潜在风险描述甚少。
对2009年8月至2016年3月期间在美国一家肝移植量最大的单一机构进行的所有肝移植术后HAS血管内干预进行回顾性研究。通过常规监测双功超声成像(收缩期峰值流速>400 cm/s、阻力指数<0.5以及存在迟滞波)确定严重HAS。
在研究期间的1129例肝移植受者中,79例患者(6.9%)因严重的初发或复发性HAS进行了106次血管造影。106例中有99例(93.4%)进行了干预,其中单纯经皮腔内血管成形术(99例中的34例)或支架置入术(99例中的65例)。即刻技术成功率为91%。106例中有8例(7.5%)发生主要并发症,包括靶血管夹层(8例中的5例)和破裂(8例中的3例)。8例患者中有6例(75%)成功进行了血管内治疗。破裂采用覆膜冠状动脉球囊扩张支架移植物或球囊压迫治疗。夹层采用裸金属或药物洗脱支架置入治疗。处理这些并发症均无需开放手术干预。中位随访22个月,8例发生主要并发症的患者中有4例(50%)进展为HAT,而71例未发生主要并发症的肝介入治疗患者中有1例(1.4%)进展为HAT(P<0.001)。1例患者需要再次移植。发生主要并发症的干预中有75%(8例中的6例)存在严重血管迂曲,而未发生主要并发症的干预中有34.6%(98例中的34例)存在严重血管迂曲(P=0.05)。在并发症队列中,37.5%(8例中的3例)患者在干预前接受了第二次肝移植,而非并发症队列中为12.6%(71例中的9例)患者(P=0.097)。
尽管HAS的血管内治疗对大多数患者安全有效,但仍有可能发生靶血管损伤。肝动脉严重迂曲和既往再次移植与主要并发症风险增加两倍至三倍相关。急性血管损伤可通过血管内技术成功处理,但这些患者随后发生HAT的风险显著,需要密切监测。